Neogen Competitors

Align Technology (NASDAQ:ALGN) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for Align Technology and Neogen, as reported by MarketBeat.com.

Align Technology presently has a consensus target price of $627.0909, suggesting a potential upside of 12.84%. Neogen has a consensus target price of $81.50, suggesting a potential downside of 10.54%. Given Align Technology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Align Technology is more favorable than Neogen.

Earnings and Valuation

This table compares Align Technology and Neogen's top-line revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 92.8% of Neogen shares are held by institutional investors. 1.2% of Align Technology shares are held by company insiders. Comparatively, 0.9% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Neogen has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Profitability

This table compares Align Technology and Neogen's net margins, return on equity and return on assets.

Summary

Align Technology beats Neogen on 12 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares West Pharmaceutical Services and Neogen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 92.8% of Neogen shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 0.9% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares West Pharmaceutical Services and Neogen's top-line revenue, earnings per share (EPS) and valuation.

West Pharmaceutical Services has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for West Pharmaceutical Services and Neogen, as reported by MarketBeat.com.

West Pharmaceutical Services presently has a consensus target price of $310.00, suggesting a potential downside of 5.81%. Neogen has a consensus target price of $81.50, suggesting a potential downside of 10.54%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, equities research analysts clearly believe West Pharmaceutical Services is more favorable than Neogen.

Risk & Volatility

West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Neogen has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Summary

West Pharmaceutical Services beats Neogen on 13 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Volatility & Risk

The Cooper Companies has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Neogen has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

Valuation and Earnings

This table compares The Cooper Companies and Neogen's top-line revenue, earnings per share (EPS) and valuation.

The Cooper Companies has higher revenue and earnings than Neogen. The Cooper Companies is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 92.8% of Neogen shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 0.9% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for The Cooper Companies and Neogen, as reported by MarketBeat.

The Cooper Companies presently has a consensus target price of $385.50, suggesting a potential downside of 1.23%. Neogen has a consensus target price of $81.50, suggesting a potential downside of 10.54%. Given The Cooper Companies' stronger consensus rating and higher probable upside, analysts clearly believe The Cooper Companies is more favorable than Neogen.

Profitability

This table compares The Cooper Companies and Neogen's net margins, return on equity and return on assets.

Summary

The Cooper Companies beats Neogen on 11 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

Neogen has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Earnings and Valuation

This table compares Neogen and DENTSPLY SIRONA's top-line revenue, earnings per share and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Neogen. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.8% of Neogen shares are held by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are held by institutional investors. 0.9% of Neogen shares are held by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neogen and DENTSPLY SIRONA, as provided by MarketBeat.com.

Neogen presently has a consensus price target of $81.50, suggesting a potential downside of 10.54%. DENTSPLY SIRONA has a consensus price target of $60.00, suggesting a potential downside of 10.22%. Given DENTSPLY SIRONA's stronger consensus rating and higher probable upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Neogen.

Profitability

This table compares Neogen and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Summary

DENTSPLY SIRONA beats Neogen on 8 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

Neogen has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Earnings and Valuation

This table compares Neogen and STAAR Surgical's top-line revenue, earnings per share and valuation.

Neogen has higher revenue and earnings than STAAR Surgical. Neogen is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.8% of Neogen shares are held by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are held by institutional investors. 0.9% of Neogen shares are held by insiders. Comparatively, 3.9% of STAAR Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neogen and STAAR Surgical, as provided by MarketBeat.com.

Neogen presently has a consensus price target of $81.50, suggesting a potential downside of 10.54%. STAAR Surgical has a consensus price target of $78.40, suggesting a potential downside of 27.41%. Given Neogen's higher probable upside, equities research analysts plainly believe Neogen is more favorable than STAAR Surgical.

Profitability

This table compares Neogen and STAAR Surgical's net margins, return on equity and return on assets.

Neogen (NASDAQ:NEOG) and Quidel (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

Neogen has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares Neogen and Quidel's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Neogen and Quidel's top-line revenue, earnings per share and valuation.

Quidel has higher revenue and earnings than Neogen. Quidel is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.8% of Neogen shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 0.9% of Neogen shares are held by insiders. Comparatively, 14.1% of Quidel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neogen and Quidel, as provided by MarketBeat.com.

Neogen presently has a consensus price target of $81.50, suggesting a potential downside of 10.54%. Quidel has a consensus price target of $182.75, suggesting a potential upside of 57.54%. Given Quidel's stronger consensus rating and higher probable upside, analysts plainly believe Quidel is more favorable than Neogen.

Summary

Quidel beats Neogen on 10 of the 14 factors compared between the two stocks.